Key result
COVID-19-related myocarditis shows no difference in one-year event-free survival versus non-COVID-19 myocarditis.
Why the study?
COVID myocarditis has a substantial influence on outcomes, and cardiac magnetic resonance plays a pivotal prognostic role, but comparative data on myocardial injury patterns and outcomes versus non-COVID myocarditis were needed.
Does COVID-19-related myocarditis have different myocardial injury patterns and clinical outcomes compared to non-COVID-19-related myocarditis?
Cohort (n=124)
Yes
Does COVID-19-related myocarditis have different myocardial injury patterns and clinical outcomes compared to non-COVID-19-related myocarditis?
Despite differing CMR injury patterns, COVID-19-related myocarditis and non-COVID-19-related myocarditis have similar one-year MACE and survival outcomes.
Answers are grounded in this paper and cite their sources.
Comparable one-year outcomes observed in this cohort; leaves open whether COVID-19 etiology alters longer-term prognosis.
Purpose: Despite the low incidence of COVID myocarditis, its influence on outcomes is substantial. The pivotal role of cardiac magnetic resonance (CMR) in diagnosing myocarditis is considered to be associated with disease prognosis. The primary objective of this study was to conduct a comparative analysis of myocardial injury patterns, CMR pathologic features, outcomes, and their correlation with CMR findings in COVID- and non-COVID-related myocarditis. Material and methods: This historical cohort study involved 124 patients diagnosed with myocarditis (COVID-19 or non-COVID-19), who underwent CMR between 2018 and 2021. The COVID group consisted of 70 individuals with a definite history of COVID-19 infection within 4 weeks, and the non-COVID group comprised 54 individuals who had no prior exposure to the SARS-CoV-2 virus. All patients were monitored for one year to assess the incidence of major adverse cardiovascular events (MACE). Additionally, baseline and follow-up echocardiography data were obtained with a minimum 3-month interval. Extension of late gadolinium enhancement (LGE) was significantly greater in COVID group. Finally, the incidence of MACE and mean event-free survival did not have significant difference between two groups. Conclusions: Although CMR findings differed between the 2 groups, there was no significant difference in the risk of MACE or survival during one-year follow-up. Notably, LV and RV dysfunction were more prevalent in the non-COVID group, while extension of LGE was greater in the COVID group.
No takes yet. Share an insight, caveat, or question.
Hajsadeghi et al. (2025) conducted a cohort in Myocarditis (COVID-19 or non-COVID-19) (n=124). COVID-19-related myocarditis vs. Non-COVID-19-related myocarditis was evaluated on Mean event-free survival (months) (p=0.353). COVID-19-related myocarditis showed no significant difference in mean event-free survival over a one-year follow-up compared to non-COVID-19 myocarditis (10.7 vs 10.1 months, p=0.353).
Synapse has enriched 10 related papers. Consider them for comparative context: